Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes

Ann Intern Med. 2020 Oct 6;173(7):595-596. doi: 10.7326/L20-1056.

Authors

Emanuele Angelucci¹, Peter Greenberg², Miguel Izquierdo³, Guillermo Garcia-Manero⁴

Affiliations

¹ IRCCS Ospedale Policlinico San Martino, Genova, Italy (E.A.).
² Stanford University Medical Center, Stanford, California (P.G.).
³ Novartis Pharma AG, Basel, Switzerland (M.I.).
⁴ MD Anderson Cancer Center and University of Texas, Houston, Texas (G.G.).

PMID: 33017548
DOI: 10.7326/L20-1056

No abstract available

Publication types

Letter
Comment

MeSH terms

Blood Transfusion
Humans
Iron Chelating Agents / therapeutic use
Myelodysplastic Syndromes* / therapy
Patients

Substances

Iron Chelating Agents